

CUMBERLAND PHARMACEUTICALS INC  
Form SC 13G  
February 09, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

SCHEDULE 13G  
Under the Securities Exchange Act of 1934  
(Amendment No. 8)\*

---

Cumberland Pharmaceuticals Inc.

---

(Name of Issuer)

Common Stock

---

(Title of Class of Securities)

230770109

---

(CUSIP Number)

December 31, 2017

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to \*the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 230770109

NAMES OF REPORTING PERSONS.

1

A.J. Kazimi

CHECK THE APPROPRIATE BOX IF  
A MEMBER OF A GROUP (SEE  
INSTRUCTIONS) Not applicable

2

(a) o

(b) o

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF  
ORGANIZATION

United States

SOLE VOTING POWER

5

NUMBER OF

~~830,270~~ 5,830,270

SHARES SHARED VOTING POWER

BENEFICIALLY

OWNED BY

EACH SOLE DISPOSITIVE POWER

REPORTING

PERSON 5,830,270

WITH: SHARED DISPOSITIVE POWER

8

None

AGGREGATE AMOUNT

BENEFICIALLY OWNED BY EACH

9 REPORTING PERSON

5,830,270

CHECK IF THE AGGREGATE  
AMOUNT IN ROW (9) EXCLUDES  
CERTAIN SHARES (SEE  
INSTRUCTIONS)

10

Not applicable

o

11 PERCENT OF CLASS

REPRESENTED BY AMOUNT IN  
ROW (9)

36.2%

12 TYPE OF REPORTING PERSON (SEE  
INSTRUCTIONS)

IN

Page 2 of 5 pages

---

Item 1.

(a) Name of Issuer

Cumberland Pharmaceuticals Inc.

(b) Address of Issuer's Principal Executive Offices

2525 West End Avenue, Suite 950, Nashville, TN 37203

Item 2.

(a) Name of Person Filing

A.J. Kazimi

(b) Address of Principal Business Office or, if none, Residence

2525 West End Avenue, Suite 950, Nashville, TN 37203

(c) Citizenship

United States

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

230770109

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership.

(a) Amount beneficially owned:

5,830,270

(b) Percent of class:

36.2%



(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

5,830,270

(ii) Shared power to vote or to direct the vote

None.

(iii) Sole power to dispose or to direct the disposition of

5,830,270

(iv) Shared power to dispose or to direct the disposition of

None.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certification

Not applicable

Page 4 of 5 pages

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 9, 2018

Date

/s/ A.J. Kazimi\*

Signature

A.J. Kazimi, Chairman and Chief Executive Officer

Name/Title

\* By: /s/ Michael Bonner, as attorney-in-fact, pursuant to a Power of Attorney dated April 26, 2016 and filed with the SEC on May 27, 2016.

Page 5 of 5 pages